Killer cell lectin-like receptor subfamily K member 1 (KLRK1) (NKG2D)

Killer cell lectin-like receptor subfamily K member 1 (NKG2D) is a potent activating receptor expressed on the surface of natural killer (NK) cells and certain T cell subsets [1]. It plays a critical role in immune surveillance by recognizing stress-induced ligands such as MICA, MICB, and ULBPs, which are typically upregulated on malignant or infected cells [2]. In the context of cord blood-derived NK (CB-NK) cells, NKG2D is a primary focus for immunotherapy, either through its natural expression or via engineering into Chimeric Antigen Receptors (CARs) [3]. CB-NK cells are particularly advantageous for clinical use due to their high proliferative potential and lower risk of inducing graft-versus-host disease compared to T-cell therapies [4]. Therapeutic strategies targeting the NKG2D pathway aim to harness its broad specificity to treat various solid and hematological cancers [5]. However, the efficacy of these treatments can be challenged by tumor-mediated shedding of soluble ligands, which acts as a decoy to downregulate receptor expression and evade immune detection [6]. Ongoing research focuses on optimizing CB-NK cell persistence and overcoming the immunosuppressive tumor microenvironment to maximize the therapeutic impact of NKG2D-mediated targeting [7].

Other names

CD314KLRK1Natural killer cell receptor 2DNKG2-D type II integral membrane protein

Activation of cytotoxic immune responses and cytokine production through the recognition of stress-induced ligands (MICA, MICB, and ULBPs) on target cells, often enhanced by CAR engineering to bypass inhibitory signals.